Contact this trialFirst, we need to learn more about you.
Muscarinic Agonist
KarXT for Schizophrenia
Recruiting2 awardsPhase 3
Torrance, California
This trial is designed to study the long-term safety and efficacy of KarXT, a fixed combination of xanomeline and trospium chloride, in patients with DSM-5 schizophrenia. The primary objective is to assess safety and tolerability, while the secondary objective is to assess long-term efficacy and monitor drug concentrations.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.